Clinical trials: Phenylephrine
Healthy
A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804
The purpose of this study is to investigate the effects of varying particle size on the pharmacokinetics of PH-797804
- Trial name
- NCT01924650
- Testing
- PH-797804
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Cesarean Section, Cardiac Output
Best Regimen for Phenylephrine Administration During Cesarean Section
During Cesarean delivery, phenylephrine is used to maintain the patient's blood pressure. Low blood pressure is the most common side effect of the spinal medication used to anesthetize the patient prior to the start of surgery.
- Conditions
- Cesarean Section, Cardiac Output, Hypotension
- Trial name
- NCT00996190
- Testing
- Phenylephrine
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Hypotension, Fluid Therapy
Phenylephrine or Norepinephrine for a Better Hemodynamic Stability
A prospective, double-blinded study. The present study consisted in applying Stroke volume variation fluid guided therapy to old patients (65 years old) undergoing radical resection of colon surgery.
- Trial name
- NCT03215797
- Testing
- phenylephrine, Norepinephrine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Healthy, Drug Abuse
Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users
The purpose of this study is to assess the abuse potential of single doses of pitolisant relative to phentermine HCl and placebo, when administered to healthy, non-dependent, recreational stimulant users.
- Trial name
- NCT03152123
- Testing
- Pitolisant, Phentermine
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bioprojet
Healthy Volunteers
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
- Trial name
- NCT02062203
- Testing
- AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Bioequivalence
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate the bioequivalence of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet…
- Trial name
- NCT02221180
- Testing
- Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated…
- Trial name
- NCT00845546
- Testing
- 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Migraine
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for…
- Trial name
- NCT03708744
- Testing
- A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zosano Pharma Corporation
Healthy Volunteers
A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib
A study in Healthy Volunteers to Compare the Amount of R406 in Blood When Given Different Formulations of Fostamatinib.
- Trial name
- Fosta BE (NCT01645085)
- Testing
- MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nasal Congestion
Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)
This study will assess the food-effect bioavailability of an extended release formulation of phenylephrine HCl and its bioequivalence to the marketed immediate release phenylephrine HCl product.
- Trial name
- NCT01354418
- Testing
- Phenylephrine HCl Extended Release, Phenylephrine HCl Immediate Release
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
The purpose of this study to evaluate the bioequivalence (is the amount same in both the pills) of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with…
- Trial name
- NCT02220218
- Testing
- Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin.
- Trial name
- NCT01325415
- Testing
- NKTR-118, moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypotension, Nausea
Ideal Dose of Phenylephrine to Treat Low Blood Pressure During Cesarean Section
The purpose of this study is to determine the minimum effective bolus dose of phenylephrine to prevent post-spinal hypotension in Cesarean section in 95 % of our patients.
- Trial name
- NCT00379691
- Testing
- phenylephrine
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Healthy
A TQT Study of Effect of M2951 on Cardiac Repolarization
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT07214935
- Testing
- Moxifloxacin, M2951 Low Dose, M2951 High Dose
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
The purpose of this study is to assess potential effects of enpatoran on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT06589726
- Testing
- Moxifloxacin, Enpatoran low dose, Enpatoran high dose
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy Women
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women
The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following single oral doses of three modified-release (MR)…
- Trial name
- NCT02112903
- Testing
- Encapsulated vortioxetine IR tablet, 20 mg, Vortioxetine MR capsule 20 mg (pH 5.5), Vortioxetine MR capsule 20 mg (pH 6.0)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market.
- Trial name
- NCT05380947
- Testing
- BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers
In the current study GSK961081 and fluticasone propionate will be administered in a blended formulation from a single device and compared with GSK961081 and fluticasone propionate administered alone and concurrently.
- Trial name
- NCT01449799
- Testing
- GSK961081 800 microgram dose, Fluticasone Propionate 500 microgram dose, GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline